Aardvark Therapeutics Stock Plunges After Exploratory HERO Trial Data Show Only Modest, Temporary Hunger Reduction

Shares of Aardvark Therapeutics dropped after limited HERO data showed only temporary benefit for ARD-101 in Prader-Willi syndrome, delaying restart to 2027.